newtonbiocapital.com Open in urlscan Pro
185.162.31.132  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Submit your business proposal
 * 日本語


 * About
 * Strategy
 * Team
 * Funds
 * Portfolio
 * News
 * Contact

 * Submit your business proposal
 * 日本語

 * About
 * Strategy
 * Team
 * Funds
 * Portfolio
 * News
 * Contact


LIFE SCIENCES INVESTMENTS


LEVERAGING INNOVATION IN EUROPE AND JAPAN





VALUE CREATION FOR ALL

Our mission is to mature innovation and support the growth of our portfolio
companies to create value for patients, society, local ecosystems, and
investors.

Get to know our portfolio!

Portfolio


ONE FUND - TWO REGIONS

Our strong ties to the life sciences ecosystems of both Europe and Japan
differentiates our fund from others and unlocks unique opportunities.

Europe and Japan both have world-class life sciences ecosystems where synergy
between the regions enables mutually beneficial gains. Through our connections
with local and international investors and pharma, we open doors to optimal
exits for our portfolio companies.

About


A STRATEGY FOR IMPACT

We support projects for promising solutions in chronic health conditions, with a
focus on alleviating patient and societal burdens.

Drawing on our team’s scientific and medical know-how, as well as a network of
experts, we seek to identify the most promising investment opportunities. We
participate proactively as board members, supporting our portfolio companies
with the selection process for their preclinical and clinical programs in a
range of technologies and disease areas.

Strategy




DO YOU THINK YOUR COMPANY WOULD BE A GOOD FIT FOR OUR PORTFOLIO?
GET IN TOUCH OR SUBMIT YOUR BUSINESS PROPOSAL TODAY!

Submit your business proposal


LATEST NEWS

19th January 2023


DEUTERONCOLOGY CLOSES €5.65M SERIES A FINANCING ROUND - BELGIAN BIOTECH COMPANY
WILL USE FUNDING TO START FIRST-IN-HUMAN CLINICAL STUDY FOR LEAD DRUG CANDIDATE
IN LUNG CANCER

Read more
13th January 2023


CELLAION SA ANNOUNCES A TOTAL FUNDRAISING OF EUR 23 MILLION IN 2022 FOR ITS
PHASE IIB STUDY IN ACUTE ON CHRONIC LIVER FAILURE

Read more
10th January 2023


UPDATE ON ACTICOR BIOTECH'S CLINICAL DEVELOPMENTS WITH GLENZOCIMAB IN THE
TREATMENT OF CARDIOVASCULAR EMERGENCIES

Read more
Life Sciences Investments - Leveraging Innovation in Europe and Japan

 * About
 * Strategy
 * Team

 * Funds
 * Portfolio
 * News

Contact
 * ESG Policy
 * Privacy policy